• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

红花注射液治疗冠心病心绞痛疗效的Meta分析

Meta-Analysis of the Effect of Honghua Injection in the Treatment of Coronary Heart Disease Angina Pectoris.

作者信息

Zhai Jiani, Ji Zhaochen, Jin Xinyao, Du Xuechen, Cao Lujia, Zheng Wenke

机构信息

Tianjin University of Traditional Chinese Medicine, Tianjin 301600, China.

出版信息

Evid Based Complement Alternat Med. 2022 May 25;2022:4537043. doi: 10.1155/2022/4537043. eCollection 2022.

DOI:10.1155/2022/4537043
PMID:35664946
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9159875/
Abstract

OBJECTIVE

To evaluate the effectiveness of honghua injection combined with western medicine in the treatment of coronary heart disease angina pectoris.

METHODS

Computer extensively searched PubMed, Cochrane Library, Embase, China Biomedical Archives (SinoMed), China Knowledge Network (CNKI), Chinese Journal Full-text Database (VIP), Wanfang Data Knowledge Service Platform (Wanfang), and collected randomized controlled trials (RCTs) of honghua injection combined with western medicine in the treatment of coronary heart disease angina pectoris. Use Review Manager5.3 software for meta-analysis.

RESULTS

21 RCTs were included, involving 1894 participants. Meta-analysis shows that honghua injection combined with western medicine can significantly improve the clinical efficacy (OR = 4.03, 95% CI[2.96,5.49]), electrocardiographic efficacy (OR = 3.39, 95%CI[2.44, 4.70]), can significantly reduce total cholesterol (TC) levels (MD = -0.39, 95% CI[-0.47, -0.31]), triacylglycerol (TG) levels (MD = -0.45, 95% CI[-0.51, -0.39]), increase high-density lipoprotein cholesterol (HDL-C) levels (MD = 0.29,95%CI[0.26,0.32]), reduce low-density lipoprotein Cholesterol (LDL-C) levels (MD = -0.59, 95%CI[-0.79, -0.38]). Five articles reported adverse reactions.

CONCLUSION

Honghua injection combined with western medicine is more effective than western medicine alone in patients with coronary heart disease angina pectoris. More multicenter, large sample, high-quality RCTs are needed to provide evidence.

摘要

目的

评价红花注射液联合西药治疗冠心病心绞痛的疗效。

方法

通过计算机广泛检索PubMed、Cochrane图书馆、Embase、中国生物医学文献数据库（SinoMed）、中国知网（CNKI）、中文科技期刊全文数据库（VIP）、万方数据知识服务平台（万方），收集红花注射液联合西药治疗冠心病心绞痛的随机对照试验（RCT）。采用Review Manager5.3软件进行Meta分析。

结果

纳入21项RCT，涉及1894例参与者。Meta分析显示，红花注射液联合西药能显著提高临床疗效（OR = 4.03，95%CI[2.96，5.49]）、心电图疗效（OR = 3.39，95%CI[2.44，4.70]），能显著降低总胆固醇（TC）水平（MD = -0.39，95%CI[-0.47，-0.31]）、三酰甘油（TG）水平（MD = -0.45，95%CI[-0.51，-0.39]），升高高密度脂蛋白胆固醇（HDL-C）水平（MD = 0.29，95%CI[0.26，0.32]），降低低密度脂蛋白胆固醇（LDL-C）水平（MD = -0.59，95%CI[-0.79，-0.38]）。5篇文章报道了不良反应。

结论

红花注射液联合西药治疗冠心病心绞痛患者比单纯西药治疗更有效。需要更多多中心、大样本、高质量的RCT提供证据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2c9/9159875/63988f61e631/ECAM2022-4537043.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2c9/9159875/047be16b2502/ECAM2022-4537043.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2c9/9159875/4b0f40ca2f28/ECAM2022-4537043.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2c9/9159875/45c6220693df/ECAM2022-4537043.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2c9/9159875/d2e387117253/ECAM2022-4537043.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2c9/9159875/fda7dadd99c7/ECAM2022-4537043.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2c9/9159875/03fb5aa19099/ECAM2022-4537043.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2c9/9159875/69cb2f662a92/ECAM2022-4537043.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2c9/9159875/673941133c62/ECAM2022-4537043.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2c9/9159875/63988f61e631/ECAM2022-4537043.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2c9/9159875/047be16b2502/ECAM2022-4537043.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2c9/9159875/4b0f40ca2f28/ECAM2022-4537043.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2c9/9159875/45c6220693df/ECAM2022-4537043.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2c9/9159875/d2e387117253/ECAM2022-4537043.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2c9/9159875/fda7dadd99c7/ECAM2022-4537043.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2c9/9159875/03fb5aa19099/ECAM2022-4537043.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2c9/9159875/69cb2f662a92/ECAM2022-4537043.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2c9/9159875/673941133c62/ECAM2022-4537043.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d2c9/9159875/63988f61e631/ECAM2022-4537043.009.jpg

相似文献

1
Meta-Analysis of the Effect of Honghua Injection in the Treatment of Coronary Heart Disease Angina Pectoris.红花注射液治疗冠心病心绞痛疗效的Meta分析
Evid Based Complement Alternat Med. 2022 May 25;2022:4537043. doi: 10.1155/2022/4537043. eCollection 2022.
2
[Network Meta-analysis of oral Chinese patent medicines in treating type 2 diabetes mellitus complicated with angina pectoris of coronary heart disease].[口服中成药治疗2型糖尿病合并冠心病心绞痛的网络荟萃分析]
Zhongguo Zhong Yao Za Zhi. 2023 Sep;48(18):5078-5090. doi: 10.19540/j.cnki.cjcmm.20230601.502.
3
Effect of Traditional Chinese Medicine combined with Western Medicine on blood lipid levels and inflammatory factors in patients with angina pectoris in coronary heart disease identified as intermingled phlegm and blood stasis syndrome: a network Meta-analysis.中药联合西药对冠心病痰瘀互结证心绞痛患者血脂水平及炎症因子的影响：网状 Meta 分析。
J Tradit Chin Med. 2023 Aug;43(4):640-649. doi: 10.19852/j.cnki.jtcm.20230506.001.
4
[Network Meta-analysis of Chinese medicine injection combined with conventional western medicine in treatment of stable angina pectoris].[中药注射剂联合西药治疗稳定型心绞痛的网络荟萃分析]
Zhongguo Zhong Yao Za Zhi. 2023 Mar;48(6):1652-1663. doi: 10.19540/j.cnki.cjcmm.20220907.503.
5
Tongxinluo Capsule Combined with Atorvastatin for Coronary Heart Disease: A Systematic Review and Meta-Analysis.通心络胶囊联合阿托伐他汀治疗冠心病：一项系统评价与Meta分析
Evid Based Complement Alternat Med. 2021 Jul 17;2021:9413704. doi: 10.1155/2021/9413704. eCollection 2021.
6
[Effectiveness and safety of Kudiezi injection in treating coronary angina pectoris: systematic review and Meta-analysis of randomized controlled trials].苦碟子注射液治疗冠状动脉粥样硬化性心脏病心绞痛的有效性与安全性：随机对照试验的系统评价与Meta分析
Zhongguo Zhong Yao Za Zhi. 2018 Oct;43(20):4138-4151. doi: 10.19540/j.cnki.cjcmm.20180611.014.
7
[Meta-analysis and trial sequential analysis of Shenshao Capsules in treatment of angina pectoris in coronary heart disease].[参芍胶囊治疗冠心病心绞痛的Meta分析与试验序贯分析]
Zhongguo Zhong Yao Za Zhi. 2024 Jun;49(12):3385-3395. doi: 10.19540/j.cnki.cjcmm.20240219.501.
8
[Meta-analysis and GRADE evaluation of Guanxinning Tablets in treatment of angina pectoris of coronary heart disease].冠心宁片治疗冠心病心绞痛的Meta分析及GRADE评价
Zhongguo Zhong Yao Za Zhi. 2023 Jan;48(1):247-255. doi: 10.19540/j.cnki.cjcmm.20221015.501.
9
[Network Meta-analysis of Chinese medicine injections in treatment of rheumatoid arthritis].中药注射剂治疗类风湿关节炎的网络荟萃分析
Zhongguo Zhong Yao Za Zhi. 2022 Oct;47(20):5627-5641. doi: 10.19540/j.cnki.cjcmm.20220727.501.
10
Ginkgo Leaf Extract and Dipyridamole Injection as Adjuvant Treatment for Angina Pectoris: A Meta-Analysis of 41 Randomized Controlled Trials.银杏叶提取物联合双嘧达莫注射液辅助治疗心绞痛：41项随机对照试验的Meta分析
Chin J Integr Med. 2018 Dec;24(12):930-937. doi: 10.1007/s11655-018-2557-6. Epub 2018 May 11.

引用本文的文献

1
Hydroxysafflor Yellow A Inhibits Pyroptosis and Protecting HUVECs from OGD/R via NLRP3/Caspase-1/GSDMD Pathway.羟基红花黄色素 A 通过 NLRP3/Caspase-1/GSDMD 通路抑制细胞焦亡并保护 HUVECs 免受 OGD/R 损伤。
Chin J Integr Med. 2024 Nov;30(11):1027-1034. doi: 10.1007/s11655-023-3716-y. Epub 2024 Feb 6.
2
Yangxin decoction for the treatment of angina pectoris of coronary heart disease: A systematic review of randomized controlled trial.养心汤治疗冠心病心绞痛随机对照试验的系统评价。
Medicine (Baltimore). 2022 Sep 2;101(35):e30394. doi: 10.1097/MD.0000000000030394.